LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Generated: 2026-09-04
Case ID: NM_024675.4_c.886del_20260904_153206
Framework: ACMG/AMP 2015
Variant classification summary

NM_024675.4:c.886del

PALB2  · NP_078951.2:p.(Met296Ter)  · NM_024675.4
GRCh37: chr16:23646980 AT>A  ·  GRCh38: chr16:23635659 AT>A
Gene: PALB2 Transcript: NM_024675.4
Final call
Pathogenic
PVS1 very strong PM2 supporting PM5 supporting
All criteria require review: For research and educational purposes only.
Gene
PALB2
Transcript
NM_024675.4
Protein
NP_078951.2:p.(Met296Ter)
gnomAD AF
2.478317816998534e-06 (v4.1)
ClinVar
Pathogenic
OncoKB
Likely Oncogenic
Interpretation summary
Generated evidence synthesis
1
PVS1 very strong: c.886del shifts the reading frame and creates a premature stop p.(Met296Ter) in exon 4 of 13 with predicted NMD, upstream of the p.Tyr1183 truncation boundary, in a gene where loss of function is an established disease mechanism.
2
PM2 supporting: gnomAD v4.1 total allele frequency of 0.000248% (4/1,613,998 alleles) is below the VCEP 1/300,000 (0.000333%) rarity threshold.
3
PM5 supporting: the premature stop at codon 296 lies upstream of p.Tyr1183*, the most C-terminal known pathogenic PALB2 truncation, satisfying the VCEP truncation-cutoff rule.
Final determination: Rule 4 of the PALB2 v1.2 specification is satisfied - one very strong pathogenic criterion (PVS1) plus at least two supporting pathogenic criteria (PM2, PM5), with no met benign criterion - yielding Pathogenic.
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
Criterion Status Rationale Evidence used
PVS1 Met Met at Very Strong: c.886del creates a premature stop p.(Met296Ter) in exon 4 of 13, upstream of p.Tyr1183 with predicted NMD, per the PALB2 VCEP PVS1 decision tree.
cspec pvs1_generic_framework PMID:30089731 PMID:25099575 PMID:28779002
PS1 N/A Not applicable: c.886del is a truncating frameshift (p.Met296Ter) with no splice impact (SpliceAI 0.018); PALB2 VCEP PS1 applies only to splice variants via its splicing table.
cspec pm5_candidates
PS2 N/A Not applicable: the PALB2 ClinGen specification disallows PS2 for autosomal dominant or recessive disease, and no de novo observation for c.886del exists.
cspec
PS3 N/A Not applicable: the ClinGen HBOC VCEP PALB2 v1.2 specification explicitly marks PS3 as a non-applicable criterion for PALB2.
cspec
PS4 Not assessed Not assessed: no case-control study reports c.886del individually; PALB2 truncating-variant class-level OR 4.69 (p=6.9e-6) cannot be attributed to this exact variant.
cspec PMID:28779002 PMID:25099575 PMID:30089731
PM1 N/A Not applicable: the PALB2 VCEP v1.2 does not use PM1 (missense pathogenicity unconfirmed), lists no approved critical-functional domains, and c.886del is a truncating frameshift, not missense.
cspec
PM2 Met Met (supporting): gnomAD v4.1 total AF of 0.000248% (4/1,613,998 alleles) falls below the PALB2 VCEP PM2 threshold of 1/300,000 (0.000333%).
cspec gnomad_v4 gnomad_v2 gnomad_canada
PM3 Not assessed Not assessed: no affected proband is documented with c.886del in trans with a second PALB2 pathogenic variant, and no phase or Fanconi-phenotype data exists.
cspec gnomad_v4 PMID:30089731 PMID:25099575
PM4 N/A Not applicable: the PALB2 ClinGen VCEP specification v1.2 excludes PM4, and this 1-bp deletion causes a frameshift premature stop, not an in-frame protein-length change.
cspec
PM5 Met Met (supporting): frameshift c.886del creates a premature stop at codon 296, upstream of p.Tyr1183*, satisfying the PALB2 VCEP PM5_Supporting truncation-cutoff rule.
cspec pm5_candidates PMID:30089731 PMID:25099575
PM6 N/A Not applicable: the PALB2 ClinGen specification disallows PM6 for autosomal dominant or recessive disease, and no assumed-de-novo observation for c.886del exists.
cspec
PP1 Not assessed Not assessed: no segregation or LOD data for c.886del; the PALB2 specification requires LOD >=0.3 or Bayes factor >=2:1 for supporting PP1.
cspec
PP2 N/A Not applicable: the PALB2 VCEP v1.2 prohibits PP2 (missense mechanism not confirmed or refuted for PALB2), and c.886del is a truncating frameshift, not missense.
cspec
PP3 N/A Not applicable: c.886del is a frameshift deletion creating p.Met296Ter, a truncating variant outside PP3's missense/SpliceAI scope.
cspec PMID:30089731 PMID:25099575
PP4 N/A Not applicable: the PALB2 VCEP v1.2 forbids PP4 for autosomal-dominant breast cancer, whose multiple genetic etiologies and lack of distinguishing features make phenotype-based support unusable.
cspec
PP5 N/A Not applicable: the PALB2 VCEP v1.2 declares PP5 not applicable, and ClinVar VCV000143979 has no expert-panel classification, only laboratory submissions.
cspec clinvar
BA1 Not met Not met: gnomAD v4.1 grpmax filtering AF of 0.000079% is over 1,000-fold below the PALB2 VCEP BA1 threshold of >0.1%.
cspec gnomad_v4 gnomad_v2
BS1 Not met Not met: gnomAD v4.1 grpmax filtering AF of 0.000079% is ~127-fold below the PALB2 VCEP BS1 threshold of >0.01%.
cspec gnomad_v4 gnomad_v2
BS2 Not met Not met: gnomAD v4.1 and v2.1 report zero homozygotes (0/1,613,998 and 0/251,348 alleles) and no unaffected-carrier observations, scoring 0 BS2 points.
cspec gnomad_v4 gnomad_v2 gnomad_canada
BS3 N/A Not applicable: the ClinGen HBOC VCEP PALB2 v1.2 specification explicitly marks BS3 as a non-applicable criterion for PALB2.
cspec
BS4 Not assessed Not assessed: no non-segregation or LOD data for c.886del; the PALB2 specification requires LOD <= -0.32 or Bayes factor <=0.48 for supporting BS4.
cspec
BP1 N/A Not applicable: the PALB2 VCEP BP1 supporting rule applies only to missense variants, and c.886del p.(Met296Ter) is a truncating frameshift.
cspec
BP2 N/A Not applicable: the PALB2 HBOP VCEP v1.2 declares BP2 not applicable, and no in-trans or in-cis observation of c.886del exists.
cspec
BP3 N/A Not applicable: the PALB2 ClinGen VCEP specification v1.2 excludes BP3, and the variant is a frameshift deletion, not an in-frame repeat-region indel.
cspec
BP4 N/A Not applicable: c.886del causes frameshift truncation (p.Met296Ter), not a missense or splice-region change, so BP4's SpliceAI no-impact path does not apply.
cspec PMID:30089731 PMID:25099575
BP5 N/A Not applicable: the PALB2 VCEP v1.2 declares BP5 not applicable; co-occurring pathogenic variants are expected given moderate penetrance and do not count as benign evidence.
cspec
BP6 N/A Not applicable: the PALB2 VCEP v1.2 declares BP6 not applicable, and ClinVar VCV000143979 has no expert-panel benign classification (Pathogenic, laboratory submissions only).
cspec clinvar
BP7 N/A Not applicable: BP7 is reserved for synonymous and deep intronic variants; c.886del is a protein-truncating frameshift (p.Met296Ter).
cspec PMID:30089731 PMID:25099575
Disclaimer: The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.